Svelte Medical completes 6 month follow up in initial Acrobat angioplasty system clinical trial

Svelte™ Medical Systems, Inc. is pleased to announce that it has completed 6 month follow up in its initial clinical trial with the Svelte Acrobat angioplasty system. The Svelte Acrobat is a low profile "All in One" stenting system with balloon control technology designed to reduce time and cost and improve safety in an angioplasty procedure. "This is truly a significant milestone for the Company. We are very pleased to see the excellent clinical results" said Mark Pomeranz, President and CEO of Svelte Medical Systems, Inc.

“The system has the ability to reduce time and costs in a procedure by allowing more lesions to be treated without pre-dilatation. The small size and flexibility of the system are well suited for the radial access approach.”

Doctor Alexandre Abizaid Chief of Coronary Interventions at Institute Dante Pazzanese de Cardiologia, Sao Paulo, Brazil noted, "The system has the ability to reduce time and costs in a procedure by allowing more lesions to be treated without pre-dilatation. The small size and flexibility of the system are well suited for the radial access approach." The results of the trial will be presented at upcoming international congresses.

The company has recently initiated commercial activities in Europe since receiving the CE Mark last year and plans to begin US clinical trials on the technology in 2011. The company has a drug eluting version under development using a novel non-inflammatory bio-erodible carrier for the drug.

The company and the product are highlighted on the Company website at www.sveltemedical.com.